Skip to main content


Fig. 2 | Cancer Communications

Fig. 2

From: Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer

Fig. 2

Metabolic pathways of capecitabine and pharmacologically related targets. 5-FU 5-fluorouracil, DPD dihydropyrimidine dehydrogenase, TP thymidine phosphorylase, FdUrd 5-fluorodeoxyuridine, TK thymidine kinase, dUMP deoxyuridine monophosphate, FdUMP fluorodeoxyuridine 5′-monophosphate, dTMP deoxythymidine monophosphate, DNA deoxyribonucleic acid, TYMS thymidylate synthase, 5-10 CH2FH4 5-10 methylene-tetrahydrofolate, FH2 dihydrofolate, 5-10 CH=FH4 5-10 methenyltetrahydrofolate, MTHFR methylenetetrahydrofolate reductase, DHFR dihydrofolate reductase, 5-CHOFH4 5-formyltetrahydrofolate, 5-CH3FH4 5-methyltetrahydrofolate, MS methionine synthase, FH4 tetrahydrofolate

Back to article page